OMICS and brain tumour biomarkers

British Journal of Neurosurgery

Volumn 20, Issue 5, 2006, Pages 275-280

  Petrik, Vladimir ^a   Loosemore, Alison ^a   Howe, Franklyn A ^a   Bell, B Anthony ^a   Papadopoulos, Marios C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Biomarker; Biomarker signature; Classification tree; DNA microarrays; Genetic algorithm; Genomics; Glioblastoma multiforme; Mass spectrometry; Metabolomics; Neural network; Pattern recognition; Proteomics

Indexed keywords

BIOLOGICAL MARKER;

BRAIN TUMOR; CANCER CLASSIFICATION; CANCER SURVIVAL; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC ACCURACY; DNA MICROARRAY; GENETIC ALGORITHM; GENOMICS; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; METABOLOMICS; MICROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATTERN RECOGNITION; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; TUMOR BIOPSY;

BIOPSY; BRAIN NEOPLASMS; CEREBROSPINAL FLUID; GENETIC MARKERS; GENOMICS; HUMANS; NEURAL NETWORKS (COMPUTER); OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATTERN RECOGNITION, AUTOMATED; PROTEOMICS; SOFTWARE; TUMOR MARKERS, BIOLOGICAL;

EID: 33845254565     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.1080/02688690600999620     Document Type: Review

References (74)

1. Murphy M, Loosemore A, Ferrer I, Wesseling P, Wilkins PR, Bell BA. Neuropathological diagnostic accuracy. Br J Neurosurg 2002;16(5):461-4.
2. Field M, Witham TF, Flickinger JC, Kondziolka D, Lunsford LD. Comprehensive assessment of hemorrhage risks and outcomes after stereotactic brain biopsy. J Neurosurg 2001;94(4):545-51.
3. Regis J, Bouillot P, Rouby-Volot F, Figarella-Branger D, Dufour H, Peragut JC. Pineal region tumors and the role of stereotactic biopsy: review of the mortality, morbidity, and diagnostic rates in 370 cases. Neurosurgery 1996;39(5):907-12; discussion 912-14.
4. Soo TM, Bernstein M, Provias J, Tasker R, Lozano A, Guha A. Failed stereotactic biopsy in a series of 518 cases. Stereotact Funct Neurosurg 1995;64(4):183-96.
5. Fritsch MJ, Leber MJ, Gossett L, Lulu BA, Hamilton AJ. Stereotactic biopsy of intracranial brain lesions. High diagnostic yield without increased complications: 65 consecutive biopsies with early postoperative CT scans. Stereotact Funct Neurosurg 1998;71(1):36-42.
6. Bernstein M, Parrent AG. Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. J Neurosurg 1994;81(2):165-8.
7. DOH. Hospital Episode Statistics. Available at: http://www. hesonline.nhs.uk/Ease/servlet/DynamicPageBuild?siteID=1802& categoryID=192&catName=Free%20data (accessed: 16 October 2005).
8. Kleihues P, Cavenee WK. Pathology and genetics: tumours of the nervous system. Lyon: International Agency for Research on Cancer, 2000.
9. Kreth FW, Warnke PC, Scheremet R, Ostertag CB. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 1993;78(5):762-6.
10. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993;78(5):767-75.
11. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95(2):190-8.
12. Polin RS, Marko NF, Ammerman MD, et al. Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres. J Neurosurg 2005;102(2):276-83.
13. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003;99(3):467-73.
14. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359(9311):1011-18.
15. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71(8):2585-97.
16. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985;56(5):1106-11.
17. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49(3):333-43.
18. DeAngelis LM. Brain tumors. N Engl J Med 2001;344(2):114-23.
19. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39(4):561-77.
20. Fukuda ME, Iwadate Y, Machida T, et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 2005;65(12):5190-4.
21. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z. Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B 2005;6(1):4-10.
22. Zheng PP, Hop WC, Sillevis Smitt PA, et al. Low-molecular weight caldesmon as a potential serum marker for glioma. Clin Cancer Res 2005;11(12):4388-92.
23. Papadopoulos MC, Abel PM, Agranoff D, et al. A novel and accurate diagnostic test for human African trypanosomiasis. Lancet 2004;363(9418):1358- 63.
24. Ardekani AM, Liotta LA, Petricoin EF III. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2002;2(4):312-20.
25. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002;62(15):4364-8.
26. Papadopoulos MC, Saadoun S, Davies DC, Bell BA. Emerging molecular mechanisms of brain tumour oedema. Br J Neurosurg 2001;15(2):101-8.
27. Alaiya A, Al-Mohanna M, Linder S. Clinical cancer proteomics: promises and pitfalls. J Proteome Res 2005;4(4): 1213-22.
28. Thulasiraman V, Lin S, Gheorghiu L, et al. Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands. Electrophoresis 2005;26(18):3561-71.
29. Fung ET, Yip TT, Lomas L, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 2005;115(5):783-9.
30. Khan-Farooqi HR, Prins RM, Liau LM. Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies. Neurol Res 2005;27(7):692-702.
31. Prins RM, Liau LM. Cellular immunity and immunotherapy of brain tumors. Front Biosci 2004;9:3124-36.
32. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92(25):11810-13.
33. Rege TA, Fears CY, Gladson CL. Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy. Neuro-oncol 2005;7(2):106-21.
34. Gonzalez-Martin A, Munoz-Espin D, Alonso AM, Izquierdo M. Parent phenotype and age dependence, on rat glioma tumor rejection. J Neurooncol 2004;70(1):29-34.
35. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353(12):1224-35.
36. Ribom D, Westman-Brinkmalm A, Smits A, Davidsson P. Elevated levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with low-grade gliomas. Tumour Biol 2003;24(2):94-9.
37. Ribom D, Larsson A, Pietras K, Smits A. Growth factor analysis of low-grade glioma CSF: PDGF and VEGF are not detectable. Neurol Sci 2003;24(2):70-3.
38. Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EF III, Liotta LA. CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics 2005;2(1):57-70.
39. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415(6870):436-42.
40. Schwartz SA, Weil RJ, Thompson RC, et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 2005;65(17):7674-81.
41. Segal E, Friedman N, Kaminski N, Regev A, Koller D. From signatures to models: understanding cancer using microarrays. Nat Genet 2005;37 Suppl:S38-45.
42. Mischel PS, Cloughesy TF, Nelson SF. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 2004;5(10):782-92.
43. Rhodes DR, Chinnaiyan AM. Integrative analysis of the cancer transcriptome. Nat Genet 2005;37 Suppl:S31-7.
44. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM. Mining for regulatory programs in the cancer transcriptome. Nat Genet 2005;37(6):579-83.
45. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 2005;102(16):5814-19.
46. Sallinen SL, Sallinen PK, Haapasalo HK, et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 2000;60(23):6617-22.
47. Hartmann C, Mueller W, Lass U, Kamel-Reid S, von Deimling A. Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 2005;64(1):10-14.
48. Huang H, Okamoto Y, Yokoo H, et al. Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene 2004;23(35):6012-22.
49. Neben K, Korshunov A, Benner A, et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 2004;64(9):3103-11.
50. Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 2003;163(5):1721-7.
51. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24(3):236-44.
52. Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 2001;98(19):10787-92.
53. Butte AJ, Tamayo P, Slonim D, Golub TR, Kohane IS. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc Natl Acad Sci USA 2000;97(22):12182-6.
54. Vercauteren FG, Bergeron JJ, Vandesande F, Arckens L, Quirion R. Proteomic approaches in brain research and neuropharmacology. Eur J Pharmacol 2004;500(1-3):385-98.
55. Lueking A, Cahill DJ, Mullner S. Protein biochips: a new and versatile platform technology for molecular medicine. Drug Discov Today 2005;10(11):789-94.
56. Angenendt P. Progress in protein and antibody microarray technology. Drug Discov Today 2005;10(7):503-11.
57. Iwadate Y, Sakaida T, Hiwasa T, et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004;64(7):2496-501.
58. Hiratsuka M, Inoue T, Toda T, et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 2003;309(3):558-66.
59. Zhang R, Tremblay TL, McDermid A, Thibault P, Stanimirovic D. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia 2003;42(2):194-208.
60. Villanueva J, Yanes O, Querol E, Serrano L, Aviles FX. Identification of protein ligands in complex biological samples using intensity-fading MALDI-TOF mass spectrometry. Anal Chem 2003;75(14):3385-95.
61. Zheng PP, Luider TM, Pieters R, et al. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 2003;62(8):855-62.
62. Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn Reson Q 1994;10(4):191-247.
63. Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003;49(2):223-32.
64. Burtscher IM, Skagerberg G, Geijer B, Englund E, Stahlberg F, Holtas S. Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. AJNR Am J Neuroradiol 2000;21(1):84-93.
65. Tzika AA, Zarifi MK, Goumnerova L, et al. Neuroimaging in pediatric brain tumors: Gd-DTPA-enhanced, hemodynamic, and diffusion MR imaging compared with MR spectroscopic imaging. AJNR Am J Neuroradiol 2002;23(2):322-33.
66. Wald LL, Nelson SJ, Day MR, et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997;87(4):525-34.
67. Nelson SJ, Graves E, Pirzkall A, et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging 2002;16(4):464-76.
68. Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002;222(3):715-21.
69. Graves EE, Nelson SJ, Vigneron DB, et al. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol 2001;22(4):613-24.
70. Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001;22(4):604-12.
71. Martin AJ, Liu H, Hall WA, Truwit CL. Preliminary assessment of turbo spectroscopic imaging for targeting in brain biopsy. AJNR Am J Neuroradiol 2001;22(5):959-68.
72. Valafar F. Pattern recognition techniques in microarray data analysis: a survey. Ann N Y Acad Sci 2002;980:41-64.
73. Poon TC, Hui AY, Chan HL, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005;51(2):328-35.
74. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359(9306):572-7.